Steven D. Gore, MD - Preparing for Personalized Care in Myelodysplastic Syndromes: Integrating Innovative Treatments Into a Cohesive Patient Care Model

Go online to PeerView.com/ZAW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelodysplastic syndromes (MDS) are a group of clonal myeloid neoplasms characterized by reduced and/or defective production of red blood cells, platelets, and mature granulocytes, often resulting in anemia, bleeding, increased risk of infection, and risk of transformation to AML. For many years, supportive therapy, blood transfusion, erythropoiesis-stimulating agents, and treatment of infections were the only therapies available. Subsequently, DNA methyltransferase inhibitors and immunomodulators showed survival benefits in MDS, leading to additional research on the efficacy of novel erythroid maturation agents in the setting of MDS-related anemia. Currently, multiple innovative therapies—including multikinase inhibitors, NEDD8-activating enzyme inhibitors, isocitrate dehydrogenase 1/2 inhibitors, BCL-2 inhibitors, and CD47 antibodies—are being investigated to improve care across different MDS populations, including low-, intermediate-, or high-risk patients, elderly individuals with comorbid conditions, and those ineligible for intensive treatment. At a recent CME web broadcast, an expert panel discussed the diagnosis and management of MDS. The panelists reviewed innovative treatment strategies, prognostic scoring systems for risk stratification, and how hematologist-oncologists can recommend appropriate therapeutic options for patients with MDS. Upon completion of this activity, participants should be better able to: Recognize the pathophysiology, clinical features, and modern prognostic scoring system for risk stratification in myelodysplastic syndromes (MDS), Identify mechanisms of action and safety-efficacy data of currently available and novel investigational agents in the settings of low-, intermediate-, and high-risk groups as well as MDS with adverse or targetable genetic features, Select risk-adapted therapeutic strategies for patients with MDS, based on the prognostic scoring systems and baseline factors such as patient age and comorbid conditions, Develop individualized treatment plans based on the potential use of novel and emerging combination therapies for managing high-risk MDS with targetable genetic mutations.